A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma.

We have examined the efficacy, toxicity and host immunological response of two different dose schedules of interleukin 2 (IL-2) given subcutaneously, daily for 3 months in patients with renal cell carcinoma (RCC) or metastatic melanoma (MM). We also examined the effect of adding the immune modulator...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ahmed, F. Y., Leonard, G. A., A'Hern, R., Taylor, A. E., Lorentzos, A., Atkinson, H., Moore, J., Nicolson, M. C., Riches, P. G., Gore, M. E.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 1996
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2077131/
https://ncbi.nlm.nih.gov/pubmed/8855983
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados